scholarly journals Ki-67 and p53 as Prognostic Factors for Luminal Type Breast Cancer

2013 ◽  
Vol 1 (1) ◽  
pp. 21-27 ◽  
Author(s):  
Ki Ho Kim ◽  
Byung Joo Chae ◽  
Byung Joo Song ◽  
Sang Seol Jung
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Ki 67 ◽  
Luminal Type

Comparison of risk categories defined by Ki-67 and the EndoPredict test in luminal-type breast cancer

2018 ◽  
Author(s):  
A Noske ◽  
J Ettl ◽  
SI Anders ◽  
A Hapfelmeier ◽  
K Steiger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ki 67 ◽  
Luminal Type ◽  
Risk Categories

scholarly journals Prominent Prognostic Factors in Aggressive Breast Cancer: A Review

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Kazem Nejati ◽  
Sedigheh Fekri Aval ◽  
Mohammadreza Alivand ◽  
Abolfazl Akbarzadeh ◽  
AmirAhmad Arabzadeh
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Lymph Node Status ◽  
Cancer Type ◽  
Ki 67 ◽  
Increased Risk ◽  
Aggressive Breast Cancer ◽  
Breast Cancer Type

Context: Breast cancer (BC) is the most common cancer in women worldwide. Hereditary susceptibility created by mutations in autosomal dominant genes is responsible for 5 to 10% of all BC cases in women. Recent studies have identified genes associated with increased risk for aggressive BC, providing the basis for better risk management. Evidence Acquisition: The latest information in National Center for Biotechnology Information (NCBI), Google Scholar, ScienceDirect, and Scopus were the main databases for finding articles. A combination of keywords of ‘metastasis’, ‘invasion’, ‘aggressive breast cancer’, ‘prognostic factor’, ‘mutation’, and ‘cancer treatment’ was searched in the databases to identify related articles. Titles and abstracts of the articles were studied to choose the right articles. Results: Mutations in breast cancer type 1 susceptibility protein (BRCA1) and breast cancer type 2 susceptibility protein (BRCA2) genes are two central players related to the high risk of BC. Mutation in tumor protein p53 (TP53) is another important mutation that leads to triple-negative BC. Although the majority of BC types are not associated with high-throughput mutant genes such as BRCA1, BRCA2, and TP53, they are associated with low-throughput genes, including DNA repair protein Rad50 (RAD50), Nijmegen breakage syndrome gene (NBS1), checkpoint kinase 2 (CHEK2), BRCA1-interacting protein 1 (BRIP1), E-cadherin gene (CDH1) and PALB2, UCHL1, aldehydedehydrogenase1A3 (ALDH1A3), androgen receptor (AR), 5-bisphosphate 3-kinase (PIK3CA), phosphatidylinositol-4, and luminal gene expression that are generally mutated in the global population. High tumor mutational burden (TMB) was associated with improved progression-free survival. Conclusions: The lymph node status, early tumor size, ER, PR, human epidermal growth factor receptor-2 (HER2), and Ki-67 are conventional prognostic factors for BC. However, these factors cannot exactly predict the aggressive behavior of BC. Hence, in this review, we discussed new prognostic factors of aggressive BCs that are useful for the treatment of patients with BC.

Igf-Ii Mrna Expression in Breast Cancer: Predictive Value and Relationship to Other Prognostic Factors

2010 ◽  
Vol 25 (3) ◽  
pp. 150-156 ◽  
Author(s):  
Emilio Fiore ◽  
Daniela Campani ◽  
Ilaria Muller ◽  
Valentina Belardi ◽  
Elisa Giustarini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Mrna Expression ◽  
Ductal Carcinoma ◽  
P53 Protein ◽  
Independent Predictive Factor ◽  
Ki 67 ◽  
P53 Expression ◽  
Predictive Parameters ◽  
The Difference

Purpose Insulin-like growth factor-II (IGF-II) is an important regulator of tumor growth in breast cancer. In this study we have examined the prognostic value of IGF-II mRNA expression in breast cancer and its relationship to other predictive parameters. Patients Sixty-eight women with infiltrating ductal carcinoma were given the same treatments including mastectomy and antitumoral therapies and followed up for 5 years. Results The overall 5-year survival rate was 73.5% (55/68). IGF-II mRNA was expressed in 33/64 patients (51.6%) and had no significant impact on survival. The expression of estrogen receptor (ER) and progesterone receptor (PgR) did not significantly affect the 5-year survival, but in the presence of an IGF-II mRNA signal, the survival of ER- and PgR-negative patients (n=9) was lower than that of ER- and PgR-positive patients (n=15), although the difference was not significant. The 5-year survival was not significantly different between Ki-67-positive and negative patients, but in the IGF-II positive group Ki-67-positive patients (n=7) had a significantly poorer prognosis than Ki-67-negative patients (n=26). The expression of p53 protein was associated with a poorer prognosis: 6/11 (54.5%) p53-positive patients died in the first 26 months of follow-up and 5 of these 6 patients (83.3%) also had positive IGF-II mRNA expression. Conclusions IGF-II mRNA expression per se is not an independent predictive factor in breast cancer but may be a marker of poor prognosis when associated with other prognostic factors such as Ki-67 index and p53 expression.

Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1096-1096
Author(s):  
Frederik Marme ◽  
Justo Lorenzo Bermejo ◽  
Hans-Peter Sinn ◽  
Peter Lichter ◽  
Florian Schuetz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Phase I ◽  
Survival Data ◽  
Primary Breast Cancer ◽  
Univariate Analysis ◽  
Pathologic Complete Response ◽  
Small Sample ◽  
Ki 67 ◽  
Significant Difference

1096 Background: We previously reported primary end points of two consecutive phase I/II trials which evaluated two different schedules of neoadjuvant gemcitabine (G), epirubicin (E) and docetaxel (Doc) for primary breast cancer. Here we report mature survival data and evaluate prognostic factors for disease-free (DFS) and overall survival (OS). Methods: 151 patients were treated in two phase I/II trials of G, E and Doc as neoadjuvant chemotherapy (NAC) for T2-4 N0-2 M0 PBC between Feb. ’02 and Dec. ’04. Patients were treated with six cycles of GEDoc (G 800mg/m2 day (d) 1+8, E 60-90mg/m2 d 1, Doc 60-75mg/m2 d 1 every three weeks) or five cycles of G 1250mg/m2 plus E 90-100mg/m2 every two weeks followed sequentially by four cycles of Doc 80-100mg/m2 every two weeks (GEsDoc). Pathologic complete response (pCR), clinical/pathological factors were correlated with DFS and OS. Results: There was no significant difference in DFS or OS between patients in the GEDoc and GEsDoc trial (DFS: Hazard ratio (HR) 1.13, p=0.67; OS: HR 1.06, p=0.88) with a 5-year DFS and OS of 72 vs 74% and 85 vs 86%, respectively. In an univariate analysis pCR unexpectedly was associated with a worse OS (HR 3.11; p= 0.007). HR for DFS showed a similar but non-significant trend (HR 1.78; p=0.1). Molecular subtypes (OS: HR [lum B] 3.17; [triple negative] 5.81; [HER2] 11.5; p=0.002), negative estrogen receptor (ER) status (OS: HR 3.14; p=0.002) and Ki-67 >20% (OS: HR 5.41; p=0.001) were all significantly associated with DFS and OS. The recently published CPS-EG score (Mittendorf 2011) was also significantly correlated with OS (p=0.006) and DFS (p=0.0006). In a multivariate analysis high Ki-67 was the only significant predictor of OS (HR 10.4; p=0.0026) whereas molecular subtype (p=0.05) and Ki-67 (p=0.04) were significantly associated with DFS. Conclusions: These results raise caution on the reliability of pCR as a single surrogate marker for survival in trials with small sample sizes. Our results emphazise the role of additional factors, esp. Ki-67 and subtypes. Integrative scores based on clinical and pathologic stage as well as tumor biology, might be more reliable predictors of survival.

Breast cancer after IVF: Can ovary stimulation and follicular response affect prognostic factors?

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12538-e12538
Author(s):  
Maxim Izquierdo ◽  
Sonia Baulies ◽  
Marta Devesa ◽  
Fransec Tresserra ◽  
Carmen Ara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Prognostic Factors ◽  
Progesterone Receptor ◽  
Ovarian Response ◽  
Histologic Grade ◽  
Breast Cancer Patients ◽  
Normal Response ◽  
Ki 67 ◽  
Follicular Response

e12538 Background: The ovary stimulation and the follicular response is related with estradiol level. Study in breast cancer patients after IVF if ovarian response or number of IVF cycles affects the prognostic factors. Methods: Patients with breast cancer who underwent IVF are studied the prognostic factors (Ki67, HER2, estrogen receptor (ER), progesterone receptor (PR), oncogene p53, histologic grade) in relation to the ovary response and number of IVF cycles. Results: 73 patients with breast cancer after IVF are studied. They performed 135 cycles of IVF, 36 (49’3%) with 1 IVF and 37 (50’7%) with more than one IVF. Hyper response was present in at least one IVF in 24 (32.9%) patients and there was no hyper response in any IVF in 49 (67.1%) patients. The prognostic factors were: Ki 67> 20 in 31'91% (15/47) Ki 67 <20 in 68'08% (32/47), HER2 + 31'94% (23/72) HER2- 68'05% (49/72), p53 + 45'09% (23/51), p53-54'90% (28/51), HG II-III 56'36% (31/55), HG I 43'63% ( 24/55), RE + 87'5% (63/72), RE- 12'5% (9/72), RP + 76'38% (55/72), RP- 23'61% (17/72). None of prognostic factors varied with the ovary response (hyper response in at least one IVF cycle, normal response, normal or low response) (p=ns). The only prognostic factor that varied with the IVF number was p53 +. Patients with p53 + (23/51), 7 (30’43%) has one IVF, and 16 (69’53%) have more one IVF (p<0’05). Conclusions: In breast cancer after IVF, the ovary stimulation and the follicular response not affect Ki67, HER2, estrogen receptor, progesterone receptor, p53, and histologic grade. p53 positive is more frequent in patients with more than one IVF.

Sign in / Sign up

Export Citation Format

Share Document